Peter E Schwartz


Ontology type: schema:Person     


Person Info

NAME

Peter E

SURNAME

Schwartz

Publications in SciGraph latest 50 shown

  • 2018-12 Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2017-05 Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo in MEDICAL ONCOLOGY
  • 2016-07 Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo in BRITISH JOURNAL OF CANCER
  • 2015-12 Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2015-12 PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas in BRITISH JOURNAL OF CANCER
  • 2015-12 Joint Effect of Genotypic and Phenotypic Features of Reproductive Factors on Endometrial Cancer Risk in SCIENTIFIC REPORTS
  • 2015-10 Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis in ANNALS OF SURGICAL ONCOLOGY
  • 2015-09 PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas in BRITISH JOURNAL OF CANCER
  • 2015-07 Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro in TUMOR BIOLOGY
  • 2015-01 T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2 in CLINICAL & EXPERIMENTAL METASTASIS
  • 2014-10 Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo in BRITISH JOURNAL OF CANCER
  • 2014-01 Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel in CLINICAL & EXPERIMENTAL METASTASIS
  • 2013-07 Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy in BRITISH JOURNAL OF CANCER
  • 2013-03 Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial in BRITISH JOURNAL OF CANCER
  • 2012-10 A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer in ONCOGENE
  • 2012-04 Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy in BRITISH JOURNAL OF CANCER
  • 2012 Fertility Preservation in Gynecologic Malignancies in FERTILITY PRESERVATION
  • 2012 Clinical Aspects of Gestational Trophoblastic Disease in GESTATIONAL TROPHOBLASTIC DISEASE
  • 2011-12 Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor in BMC CANCER
  • 2011-12 Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2011-10 Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor in CLINICAL & EXPERIMENTAL METASTASIS
  • 2011-10 Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab in BRITISH JOURNAL OF CANCER
  • 2011-05-07 Gynecologic Malignancies in the Elderly in PRINCIPLES AND PRACTICE OF GERIATRIC SURGERY
  • 2010-12 Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer in BMC CANCER
  • 2010-09 hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma in BRITISH JOURNAL OF CANCER
  • 2010-01 In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma in BRITISH JOURNAL OF CANCER
  • 2009-12 Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) in BRITISH JOURNAL OF CANCER
  • 2009-11 Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer in CURRENT ONCOLOGY REPORTS
  • 2009-07 Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer in BRITISH JOURNAL OF CANCER
  • 2008-08 Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells in ONCOGENE
  • 2005-12 E-cadherin and β-catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases in WORLD JOURNAL OF SURGICAL ONCOLOGY
  • 2005-01 Minimal uterine serous carcinoma: a clinicopathological study of 40 cases in MODERN PATHOLOGY
  • 2002 Current Diagnosis and Treatment Modalities for Ovarian Cancer in OVARIAN CANCER
  • 2001-02 Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States) in CANCER CAUSES & CONTROL
  • 2001 Rare Tumors in Pregnancy in CANCER AND PREGNANCY
  • 2001 Hematologic Malignancies in Pregnancy in CANCER AND PREGNANCY
  • 2001 Radiologic Diagnosis of Cancer in Pregnancy in CANCER AND PREGNANCY
  • 1999-03 Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells in CANCER GENE THERAPY
  • 1998-12 p53 polymorphism and risk of cervical cancer in NATURE
  • 1990-05 Aberrant hormone production from ovarian neoplasms: Strategies for diagnosis and therapy in WORLD JOURNAL OF SURGERY
  • 1989-06 Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.47100.32", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.36425.36", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.261331.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.134563.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414467.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412530.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.17091.3e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.254656.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7605.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419047.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417307.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417397.f", 
            "type": "Organization"
          }
        ], 
        "familyName": "Schwartz", 
        "givenName": "Peter E", 
        "id": "sg:person.01207015645.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207015645.37"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T15:07", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_807.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01207015645.37'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01207015645.37'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01207015645.37'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01207015645.37'


     

    This table displays all metadata directly associated to this object as RDF triples.

    38 TRIPLES      10 PREDICATES      22 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01207015645.37 schema:affiliation N0f3def9bd78b439e931d32e19249c8a3
    2 https://www.grid.ac/institutes/grid.134563.6
    3 https://www.grid.ac/institutes/grid.17091.3e
    4 https://www.grid.ac/institutes/grid.254656.6
    5 https://www.grid.ac/institutes/grid.261331.4
    6 https://www.grid.ac/institutes/grid.36425.36
    7 https://www.grid.ac/institutes/grid.412530.1
    8 https://www.grid.ac/institutes/grid.414467.4
    9 https://www.grid.ac/institutes/grid.417307.6
    10 https://www.grid.ac/institutes/grid.417397.f
    11 https://www.grid.ac/institutes/grid.419047.f
    12 https://www.grid.ac/institutes/grid.7605.4
    13 schema:familyName Schwartz
    14 schema:givenName Peter E
    15 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207015645.37
    16 schema:sdDatePublished 2019-03-07T15:07
    17 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    18 schema:sdPublisher N887c0e8e0e5a49778e2e2e4d4c22f54c
    19 sgo:license sg:explorer/license/
    20 sgo:sdDataset persons
    21 rdf:type schema:Person
    22 N0f3def9bd78b439e931d32e19249c8a3 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
    23 sgo:isCurrent true
    24 rdf:type schema:OrganizationRole
    25 N887c0e8e0e5a49778e2e2e4d4c22f54c schema:name Springer Nature - SN SciGraph project
    26 rdf:type schema:Organization
    27 https://www.grid.ac/institutes/grid.134563.6 schema:Organization
    28 https://www.grid.ac/institutes/grid.17091.3e schema:Organization
    29 https://www.grid.ac/institutes/grid.254656.6 schema:Organization
    30 https://www.grid.ac/institutes/grid.261331.4 schema:Organization
    31 https://www.grid.ac/institutes/grid.36425.36 schema:Organization
    32 https://www.grid.ac/institutes/grid.412530.1 schema:Organization
    33 https://www.grid.ac/institutes/grid.414467.4 schema:Organization
    34 https://www.grid.ac/institutes/grid.417307.6 schema:Organization
    35 https://www.grid.ac/institutes/grid.417397.f schema:Organization
    36 https://www.grid.ac/institutes/grid.419047.f schema:Organization
    37 https://www.grid.ac/institutes/grid.47100.32 schema:Organization
    38 https://www.grid.ac/institutes/grid.7605.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...